Abstract
Angiogenesis is a cornerstone in the process of hepatocarcinogenesis. In the sorafenib era, other antiangiogenic targeted drugs, such as monoclonal antibodies and a new generation of tyrosine kinase inhibitors, have been shown in phase II trials to be safe and effective in the treatment of advanced hepatocellular carcinoma. Several currently active phase III trials are testing these drugs, both in first- and second-line settings. Strategies to overcome primary and acquired resistance to antiangiogenic therapy are urgently needed. Novel biomarkers may help in improving the efficacy of drugs targeting angiogenesis.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2011) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. International Agency for Research on Cancer 2010, Lyon, France. http://globocan.iarc.fr. Accessed 15 September 2011
Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491
American Cancer Society (2010) Cancer facts and figures 2010. American Cancer Society, Atlanta
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538
Liaw YF, Chu CM (2006) Hepatitis B virus infection. Lancet 373:582–592
Armstrong GL, Wasley A, Simard EP et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714
Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM (2004) Obesity and hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S97–S103
Siegel AB, Zhu AX (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115:5651–5661
Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15(4 Suppl):14–22
Palmer DH, Hussain SA, Johnson PJ (2004) Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 13:1555–1568
Zhu A (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11:790–800
Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327
Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129–3140
Chen KF, Tai WT, Liu TH et al (2010) Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16(21):5189–5199
Llovet JM, Ricci S, Mazzaferro V et al (2008) SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300
Verslype C, Van Cutsem E, Dicato M et al (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20(7 Suppl):vii1–vii6
Peck-Radosavljevic M, Greten TF, Lammer J et al (2010) Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 22:391–398
Sun H, Tang Z (2004) Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 130:307–319
Pang R, Poon RT (2006) Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242:151–167
Hoshida Y, Toffanin S, Lachenmayer A et al (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30:35–51
Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis of human hepatocellular carcinoma: from genes to environment. Nat Rev Cancer 6:674–687
Suzuki K, Hayashi N, Miyamoto Y et al (1996) Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004–3009
Miura H, Miyazaki T, Kuroda M et al (1997) Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27:854–861
Abou-Alfa G, Johnson P, Knox J et al (2010) Doxorubicin plus sorafenib vs. doxorubicin alone in patients with advanced hepatocellular carcinoma. JAMA 19:2154–2160
Griffiths L, Stratford IJ (1997) Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br J Cancer 76:689–693
Asahara T, Bauters C, Zheng LP et al (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92(9 Suppl):II365–II371
Zhang ZL, Liu ZS, Sun Q (2006) Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 12:4241–4245
Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19:329–337
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Eng J Med 285:1182–1186
Brun P, Castagliuolo I, Pinzani M, Palù G, Martines D (2005) Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 289:G571–G578
De Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37
Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618–631
Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78
Zhu AX, Dushyant VS, Duda DG et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035
Butler JM, Kobayashi H, Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10:138–146
Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201
Cao Y, Zhong W, Sun Y (2009) Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 19:338–343
Siegel AB, Cohen EI, Ocean A et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992–2998
Ho J, Pang R, Lau C et al (2006) Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44:836–843
Sieghart W, Fellner S, Reiberger T et al (2009) Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. Dig Liver Dis 41:902–906
Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027
Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G (2000) Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J Biol Chem 275:18040–18045
Schmitt M, Horbach A, Kubitz R, Frilling A, Häussinger D (2004) Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41:274–283
Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438:820–827
Chouaib S, Kieda C, Benlalam H et al (2010) Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 30:529–545
Carmeliet P, Moons L, Luttun A et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575–583
Ferrara N (2005) The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94:209–231
Joukov V, Pajusola K, Kaipainen A et al (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine-kinases. EMBO J 15:290–298
Achen MG, Jeltsch M, Kukk E et al (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548–553
Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549–560
Kuhnert F, Tam BY, Sennino B et al (2008) Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 105:10185–10190
Presta M, Dell′Era P, Mitola S et al (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159–178
Park YN, Kim YB, Yang KM, Park C (2000) Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061–1065
Moon WS, Rhyu KH, Kang MJ et al (2003) Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16:552–557
Imura S, Miyake H, Izumi K, Tashiro S, Uehara H (2004) Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma. J Med Invest 51:202–209
Jia JB, Zhuang PY, Sun HC et al (2009) Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 135:847–854
Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ (2009) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100:1385–1392
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603
Tavakoli J, Aragon-Ching JB (2010) Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors. Anticancer Agents Med Chem 10:593–600
Ebos JM, Lee CR, Christensen JG et al (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104:17069–17074
Rapisarda A, Melillo G (2009) Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Update 12:74–80
Pazo RA, Esquerdo G, Puertolas T et al (2010) Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 28 (Suppl) (abstract e14619)
Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621
Pàez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231
Raoul JL, Finn RS, Kang YK et al (2009) An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 27 (15 Suppl) (abstract 4577)
Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309
Nissen LJ, Cao R, Hedlund EM et al (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117:2766–2777
Jin ZG, Ueba H, Tanimoto T et al (2003) Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 93:354–363
Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Shaked Y, Ciarrochi A, Franco M et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785–1787
Du R, Lu KV, Petritsch C et al (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206–220
Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factors receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337
Tang TC, Shan M, Xu P et al (2010) Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12:928–940
Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85:1301–1307
Relf M, LeJeune S, Scott PA et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963–969
Gwak GY, Yoon JH, Kim KM et al (2005) Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42:358–364
Kim KW, Bae SK, Lee OH et al (1998) Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 58:348–351
Miyoshi A, Kitajima Y, Ide T et al (2006) Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol 29:1533–1539
Piret JP, Minet E, Cosse JP et al (2005) Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 280:9336–9344
Baek JH, Jang JE, Kang CM et al (2000) Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 19:4621–4631
Zhu H, Chen XP, Luo SF et al (2005) Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 24:565–574
Williams KJ, Telfer BA, Xenaki D et al (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75:89–98
Xiong ZP, Yang SR, Liang ZY et al (2004) Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 3:386–390
Song BC, Chung YH, Kim JA et al (2001) Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 91:2386–2393
Sessa C, Guibal A, Del Conte G, Ruegg C (2008) Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 5:378–391
Cheng A, Kang Y, Lin D et al (2011) Phase III trial of sunitinib (Su) vs sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29:256 (abstr 4000)
Shao YY, Lin ZZ, Hsu Ch et al (2010) Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116:4590–4596
Yau T, Yao TJ, Chan P et al (2011) The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 16:1270–1279
Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672–4678
Llovet J, Pena C, Shan M, Jeffers M, Lathia Ch, Bruix J (2008) Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from the randomized phase III SHARP trial. AASLD 59th Annual Meeting. Hepatology 48(S1) (abstract 149)
Wong ChI, Koh TS, Soo R et al (2009) Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718–4726
Zhang Z, Zhou X, Shen H, Wang D, Wang Y (2009) Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 7:41
Yamashita T, Forgues M, Wang W et al (2008) EpCAM and -fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461
Yamashita T, Budhu A, Forgues M, Wng XW (2007) Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67:10831–10839
Shan Y, Huang Y, Xie Y et al (2010) Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status. Med Oncol [Epub ahead of print]. doi:10.1007/s12032-010-9600-6
Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV (2008) Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13:120–125
Lassau N, Koscielny S, Chami L et al (2011) Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification–preliminary results. Radiology 258:291–300
Siemerink EJM, Mulder NJ, Brouwers AH, Hospers GA (2008) 18F-fluorodeoxyglucose positron emission tomography monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. Oncologist 13:734–735
Lanzuela M, Pazo Cid RA, Lao J et al (2010) Early response evaluation of sorafenib (SFB) therapy: use of computed fluorodeoxyglucose positron emission tomography (PET-CT) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 28(Suppl) (abstract e14567)
Kim BK, Kang WJ, Kim JK et al (2011) 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117:4779–4787
Cao Y (2010) Off-tumor target—beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol 7:604–608
Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949–954
Ravaud A, Sire M (2009) Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 20:966–967
Vincenzi B, Santini D, Russo A et al (2010) Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 15:85–92
Xiong YQ, Sun HC, Zhu XD et al (2011) Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol 137:505–512
Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989
Epstein RJ (2007) VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 26:443–452
Finn RS, Zhu AX (2009) Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 9:503–509
Zhu AX, Blaszkowsky LS, Ryan DP et al (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898–1903
Sun W, Sohal D, Haller DG et al (2011) Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117:3187–3192
Hsu CH, Yang TS, Hsu C et al (2010) Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 102:981–986
Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843–850
Kaseb AO, Iwasaki M, Javle M et al (2009) Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 27(15 Suppl) (abstract 4522)
Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–3714
Treiber G, On behalf of the German HCC-RAD001/Bevazicumab Multicenter Study Group (2010) Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001. J Clin Oncol 28(15 Suppl) (abstract 4102)
Yeh J, Frieze D, Martins R, Carr L (2010) Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother 44(6):1010–1015
Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305:487–494
Leighl NB, Bennouna J, Yi J et al (2011) Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 104:413–418
De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8:393–404
Ebos JM, Lee CR, Cruz-Munoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239
Gandhi L, McNamara KL, Li D, Borgman CL et al (2009) Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila) 2:330–337
Di Tomaso E, Snuderl M, Kamoun WS et al (2011) Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape. Cancer Res 71:19–28
Miles D, Harbeck N, Escudier B et al (2010) Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 29:83–88
Shao Y, Lu L, Cheng AL, Hsu CH (2011) Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. Oncologist 16:82–86
Besse B, Lasserre SF, Compton P et al (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269–278
Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172–1183
Yau T, Pang R, Chan P, Poon RT (2010) Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin Pharmacother 11:2187–2198
Spratlin JL, Cohen RB, Eadens M et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780–787
Koeberle D, Montemurro M, Samaras P et al (2010) Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). Oncologist 15:285–292
Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicenter, phase II study. Lancet Oncol 10:794–800
Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A (2010) Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 79:85–92
Liu Y, Poon RT, Li Q et al (2005) Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65:3691–3699
Murakami M, Kobayashi S, Marubashi S et al (2011) Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol 18:589–596
Yau T, Chan P, Pang R et al (2010) Phase 1–2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116:5022–5029
Drevs J, Zirrgiebel U, Schmidt-Gersbach CI et al (2005) Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558–565
Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964
Mros K, Drevs J, Muller M et al (2005) Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41:1291–1299
Thomas MB, Jaffe D, Choti MM et al (2010) Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28:3994–4005
Jonker DJ, Rosen LS, Sawyer M et al (2007) A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol 25 (abstract 3559)
Toh H, Chen P, Carr BI et al (2009) A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol 27 (15 Suppl) (abstract 4581)
Alberts SR, Morlan BW, Kim GP et al (2007) NCCTG phase II trial (N044 J) of AZD2171 for patients with hepatocellular carcinoma (HCC)—interim review of toxicity. Presented at the Gastrointestinal Cancers Symposium, Orlando, FL (abstract 186)
Yau CC, Chen PJ, Chan P et al (2011) Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 17:6914–6923
Conflict of interest
The authors declare that they have no conflict of interest relating to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
*Supported by an unrestricted educational grant from MSD Oncology.
Rights and permissions
About this article
Cite this article
Pazo-Cid, R.A., Lanzuela, M., Esquerdo, G. et al. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 14, 564–574 (2012). https://doi.org/10.1007/s12094-012-0842-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0842-y